MET overexpression, regardless MET amplification status, has been found to induce addiction to the MET pathway, and was recently found in 27.1% of EGFR mutated NSCLC with acquired resistance to EGFR TKI [29] [17]. The gene discussed is MET; the disease is non-small cell lung carcinoma.